TUDCA sits at the intersection of pharmaceutical history, modern supplement marketing, and emerging longevity claims. It has been used as a drug for cholestasis in Italy and several Asian countries since the 1980s, sold as a supplement in the US since the 2010s, and increasingly recommended in longevity stacks for mitochondrial and ER-stress-reducing properties. The evidence is uneven across these claims; this guide separates the established cases from the marketing extrapolations.
What is TUDCA?
Tauroursodeoxycholic acid (TUDCA) is a bile acid produced by conjugating ursodeoxycholic acid (UDCA) with taurine. UDCA is one of the secondary bile acids produced by gut bacteria from primary bile acids; in humans it represents only a few percent of the total bile-acid pool, but it has been used as a pharmaceutical for decades to treat cholestasis, primary biliary cholangitis, and gallstone dissolution. TUDCA is the taurine-conjugated form, which is more water-soluble than the unconjugated parent molecule and crosses biological membranes more readily.
The compound has been used in traditional Chinese medicine for centuries as an extract from bear bile. The modern pharmaceutical interest dates to the 1970s and 1980s, when European clinicians began testing it for the same indications as UDCA. TUDCA is approved as a pharmaceutical in Italy, China, and several other countries; in the US it is sold as a dietary supplement rather than a regulated drug.
See the TUDCA compound page for the full pharmacological profile, dosing detail, and evidence map per outcome.
Mechanism: bile-acid signaling and ER stress
TUDCA's mechanisms span three connected biological roles, each corresponding to one of the major use cases.
Bile-acid signaling. TUDCA modulates the FXR (farnesoid X receptor) and TGR5 nuclear receptors in liver and gut, regulating bile-acid synthesis, lipid metabolism, and intestinal barrier function. Unlike many bile acids that activate FXR strongly, TUDCA has a milder receptor effect, which contributes to its tolerability. This is the mechanism behind the established cholestasis use case.
ER stress reduction. TUDCA functions as a chemical chaperone in the endoplasmic reticulum, stabilizing misfolded proteins and reducing the unfolded protein response (UPR). This is the mechanistic case for emerging applications in ALS (where misfolded SOD1 and TDP-43 drive motor neuron death), retinitis pigmentosa (rhodopsin misfolding), and metabolic conditions characterized by ER-stress-driven beta-cell dysfunction.
Mitochondrial protection. TUDCA reduces mitochondrial outer-membrane permeabilization, blocks cytochrome c release, and dampens apoptosis signaling. The mitochondrial mechanism underpins the longevity-supplement positioning, though human outcome data on the mitochondrial use case are absent.
The connecting thread is cellular stress reduction: across all three mechanisms, TUDCA dampens stress responses that, when chronic, contribute to age-related disease. Whether the dampening produces meaningful clinical benefit at supplemental doses is the question that varies by indication.
Liver outcomes: cholestasis, NAFLD, drug-induced injury
The strongest evidence base is in liver indications.
Cholestasis and primary biliary cholangitis. The pharmaceutical case is settled. Crosignani 1996 and other early Italian trials demonstrated TUDCA reduced cholestasis markers (bilirubin, alkaline phosphatase) at 500 to 750 mg/day in PBC patients, comparable to UDCA Crosignani A et al 1996 . TUDCA is the standard of care in several countries for this indication.
Non-alcoholic fatty liver disease (NAFLD). Several small trials have reported modest improvements in liver enzymes (ALT, AST, GGT) and steatosis markers at 500 to 1,000 mg/day for 12 to 24 weeks. The trials are small and effect sizes are modest; comparison with lifestyle intervention (caloric restriction, exercise, weight loss) is unfavorable. TUDCA is not a substitute for the lifestyle interventions in NAFLD.
Drug-induced liver injury. Used clinically (off-label in many countries, on-label in others) to support liver recovery from hepatotoxic drug exposure. Evidence is supportive but lacks large modern RCTs. For users on long-term hepatotoxic medications (e.g. methotrexate, certain antifungals, anabolic agents), TUDCA at 500 mg/day alongside standard liver-monitoring labs is a defensible adjunct.
For general "liver support" without diagnosed liver disease, the marginal benefit of TUDCA at supplement doses is modest. Diet quality, alcohol intake, and metabolic health drive baseline liver function more than any supplement.
Mitochondrial outcomes: emerging signals
The mitochondrial case for TUDCA is mechanistically appealing and weakly supported in humans.
Mouse studies show preserved mitochondrial function in aging tissues with chronic TUDCA. The mechanism (reduced outer-membrane permeabilization, dampened apoptosis signaling) is the same biology that underpins the ALS and retinal applications.
In humans, no completed trial has measured mitochondrial function as a primary endpoint at supplement doses. The longevity-supplement marketing extrapolates from the mouse data and the established ER-stress mechanism. This is reasonable mechanistic reasoning but should not be treated as outcome-proven.
For users targeting mitochondrial support specifically, urolithin-a has stronger human evidence (the Andreux 2019 trial showed improved muscle endurance and mitochondrial markers). TUDCA is a secondary pick on the mitochondrial axis; primary if the underlying need is liver-related or ER-stress-related.
Brain and ER stress: ALS, retinitis pigmentosa
This is the most clinically interesting emerging area for TUDCA.
ALS. Elia 2016 (n=34, single-center RCT) reported slowed ALS Functional Rating Scale decline at 1,000 mg/day TUDCA Elia AE et al 2016 . The TUDCA + phenylbutyrate combination (Relyvrio / AMX0035, Paganoni 2020 CENTAUR trial) showed slowed ALS progression and was approved by FDA in 2022. Confirmatory trials returned mixed results in 2024 and the drug was withdrawn pending re-review. The pure-TUDCA case in ALS rests on Elia 2016 and supportive preclinical work; the combination case has been the larger investigational program.
Retinitis pigmentosa. Mouse models show clear preservation of photoreceptor function on chronic TUDCA. Small human trials in retinitis pigmentosa report stabilization of visual fields. Effect sizes are modest; the case is strongest as adjunctive therapy alongside standard care.
For both indications, users should run the decision through a specialist. Off-label TUDCA use for ALS is increasingly common; for retinitis pigmentosa, ophthalmologic monitoring should accompany supplementation.
TUDCA vs milk thistle: when each makes sense
The most asked comparative question. Different mechanisms, different use cases.
Milk thistle (silymarin) is a flavonoid antioxidant complex extracted from Silybum marianum. Its mechanisms include hepatocyte membrane stabilization, glutathione regeneration, and direct radical scavenging. The human evidence base supports modest benefits in alcoholic liver disease, viral hepatitis (adjunctive), and toxin-induced liver injury (Amanita phalloides poisoning is the classical use case). Doses: 200 to 600 mg/day silymarin standardized.
TUDCA is a bile-acid receptor agonist and chemical chaperone. The mechanisms differ from milk thistle entirely. The human evidence base supports cholestasis, drug-induced liver injury, and emerging ER-stress applications. Doses: 250 to 1,000 mg/day depending on indication.
When milk thistle is the better pick: general antioxidant liver support without cholestasis or ER-stress conditions. Lower cost. Longer historical use. Adequate for users with mild liver enzyme elevations from non-alcoholic causes.
When TUDCA is the better pick: cholestasis or impaired bile flow (the established pharmaceutical case). ALS as adjunct under specialist guidance. ER-stress-related metabolic conditions. Targeted mitochondrial support paired with urolithin-a or spermidine.
When both make sense: large chronic insults to the liver (long-term hepatotoxic medication exposure, sustained alcohol use during a transition period, severe NAFLD with specialist oversight). Combining the two at typical doses is well-tolerated.
Disadvantages and side effects
The honest counter-list.
Cost. TUDCA at 500 mg/day runs roughly 30 to 80 dollars per month at quality brands, several times the cost of milk thistle or NAC for general liver-support use.
GI side effects. Loose stools, nausea, occasional diarrhea, particularly at doses above 1,000 mg/day. Splitting the daily dose into 2 administrations with food reduces incidence.
Bear-bile-derived products. Ethically problematic and inconsistent in purity. Synthetic TUDCA (manufactured from UDCA) is the better choice; look for products specifying synthetic origin and providing a Certificate of Analysis.
Limited long-term safety data above 1,500 mg/day. Most chronic-use trials cluster at 500 to 1,000 mg/day. Sustained higher-dose use in healthy adults has not been well-characterized.
Theoretical absorption interactions. TUDCA may modestly affect absorption of fat-soluble drugs (cyclosporine, oral contraceptives, fat-soluble vitamins) by altering bile-acid pool composition. The clinical relevance at supplement doses is small; users on critical medications should consult their prescriber.
Pregnancy and lactation. Insufficient data at supplement doses. UDCA (the parent compound) is used clinically for cholestasis of pregnancy with reasonable safety, but TUDCA-specific data are limited.
Belly fat / metabolism claims: what's hype
TUDCA is sometimes marketed as a fat-loss aid or "belly fat reducer." This is not supported by the trial data.
Kars 2010 (n=20 obese non-diabetic adults, 1,750 mg/day for 4 weeks) is the most-cited metabolic trial Kars M et al 2010 . Findings: improved hepatic and muscle insulin sensitivity, no improvement in adipose tissue insulin sensitivity, no change in body weight, no change in body composition. The trial supports a metabolic-improvement signal in liver and muscle but explicitly does not support an adipose-tissue or weight-loss effect.
Other small TUDCA trials have shown similar patterns: insulin sensitivity improvements without weight changes. The "belly fat" marketing extrapolates from the insulin-sensitivity signal to a body-composition claim that the trials did not measure.
For users who want a real impact on belly fat: the fat loss protocol post covers what actually works (calorie deficit, training, sleep, dietary protein). TUDCA is a secondary metabolic tool with liver-specific effects, not a body-composition lever.
Dosage: typical 250 to 500 mg/day, daily safety
The most common protocols.
- Daily supplement use (general liver / longevity): 250 to 500 mg/day, taken with food. Split into 2 doses if 500 mg is the target.
- Cholestasis / liver support with diagnosed condition: 500 to 750 mg/day, divided into 2 doses, 12 to 24 weeks for clinical effect on liver enzymes. Run through a hepatologist.
- Metabolic / insulin sensitivity (research dose): 1,750 mg/day for 4 weeks (the Kars 2010 protocol). Not typical for chronic use.
- ALS adjunct (Elia 2016 protocol): 1,000 mg/day for 12+ months. Specialist guidance required.
Continuous dosing is the standard pattern; no formal cycling protocol is established. Periodic 2 to 4 week breaks are reasonable but not evidence-based.
With-food dosing improves tolerability; an empty stomach can produce more GI side effects.
For users new to TUDCA, starting at 250 mg/day for the first 1 to 2 weeks and titrating up if well-tolerated is a defensible approach.
Stack interactions: vitamin D, NAC, phosphatidylcholine
TUDCA pairs reasonably with several other compounds in the liver and longevity space.
- NAC (N-acetylcysteine): different mechanism (glutathione precursor); additive antioxidant liver support. Pair safely.
- Vitamin D3 + K2: standard biohacking foundation; no interaction with TUDCA at supplement doses. Pair safely.
- Phosphatidylcholine: useful for users with NAFLD or post-fatty-meal symptoms; works at the cell-membrane level. Pair safely.
- Milk thistle: different mechanism; combining is well-tolerated for users with significant liver insults (see comparison section above).
- Statins: TUDCA may modestly support liver tolerance of statins via the same drug-induced liver-injury mechanism. Discuss with prescriber if combining; bloodwork monitoring should continue per standard statin protocols.
- Active liver-pathway prescription drugs (cyclosporine, certain antifungals, methotrexate): consult prescriber. The interaction is typically modest but worth flagging.
Pairing TUDCA with urolithin-a (mitochondrial), spermidine (autophagy), and omega-3 covers a defensible mitochondrial / cellular-stress axis with broader human evidence than any single compound provides alone.
Verdict: who should consider TUDCA
TUDCA is a defensible pick for:
- Users with diagnosed cholestasis, primary biliary cholangitis, or chronic mild liver enzyme elevations (under hepatologist guidance).
- Users on long-term hepatotoxic medications who want an adjunctive liver-protective layer.
- Users with ALS or retinitis pigmentosa exploring evidence-based adjunctive options (under specialist guidance).
- Users with specific ER-stress-related metabolic conditions and a clinician familiar with the literature.
- Users in well-resourced longevity stacks who want broader cellular-stress-reduction coverage and accept the early-stage evidence framing on the mitochondrial / longevity claims.
TUDCA is probably not the right pick for:
- Users with no specific liver concerns who could use less-expensive alternatives (milk thistle, NAC) for general antioxidant support.
- Users buying it for "belly fat" or weight loss (not supported by trial data).
- Users with complete biliary obstruction or active GI disease without medical supervision.
- Users in pregnancy or lactation without clinical guidance.
The honest framing: TUDCA is a real pharmaceutical with established cholestasis evidence. The supplement-positioning extends the use case to longevity and mitochondrial claims that rest on weaker human data. Users buying supplemental TUDCA for the established indications are making a reasonable bet on a well-tolerated compound with a good safety record. Users buying it for the less-established claims should accept the early-stage evidence framing.
